Home › Compound Library › Risperidone (Risperdal)

Risperidone (Risperdal)

Antipsychoticprescriptionoral · predicted

Benzisoxazole atypical antipsychotic. Potent D2 and 5-HT2A antagonist. Rapidly converted by CYP2D6 to active metabolite paliperidone (9-hydroxyrisperidone), which is equipotent and has a much longer half-life. Combined active moiety (risperidone + paliperidone) drives clinical effect. Dose-dependent EPS risk increases >6 mg/day. Paliperidone is marketed separately as Invega. Also available as long-acting injectable (Risperdal Consta).

Projected serum levels — 2 mg, twice daily

Risperidone (Risperdal)
Risperidone (Risperdal) modeled serum levels, 2 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Risperidone (Risperdal) modeled serum levels with a loading dose of 2.6 mg, then 2 mg twice daily The first dose is larger so levels approach steady state faster. 0 0.50 1 1.5 2 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 2 mg twice daily (oral).

Loading schedule: 2.6 mg on day 1, then 2 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 1.4 mg, trough ≈ 0.42 mg body load. Population-based estimate over 15 days for a 2 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antipsychotic
Route modeled
Oral
Model confidence
predicted
Half-life
3 h
Common dose
2 mg
Suggested maximum
8 mg/day
Reference dose range
1–8 mg (single dose)
Suggested cadence
twice daily
Validated against
2 mg oral — Cmax 0.030 mg/L at 1 h

Documented interactions

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Risperidone (Risperdal) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Risperidone (Risperdal) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    4-AcO-DMT (Psilacetin) + Risperidone (Risperdal) Serotonin risk

    4-AcO-DMT (Psilacetin) and Risperidone (Risperdal) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) + Risperidone (Risperdal) Serotonin risk

    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) and Risperidone (Risperdal) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) + Risperidone (Risperdal) Serotonin risk

    6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) and Risperidone (Risperdal) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    Aripiprazole (Abilify) + Risperidone (Risperdal) Stacked effects

    Aripiprazole (Abilify) and Risperidone (Risperdal) both push the alpha1 adrenergic, histamine H1, and serotonin 5HT2A in the same direction.

  • danger
    Ayahuasca (DMT + Harmaline) + Risperidone (Risperdal) Serotonin risk

    Ayahuasca (DMT + Harmaline) and Risperidone (Risperdal) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 191 modeled interaction pairings for risperidone (risperdal) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials Leucht S et al. · Schizophrenia Research, 2009 DOI

    Meta-analysis of 30+ RCTs confirming risperidone 4-6 mg/day is significantly more effective than placebo and typical antipsychotics for schizophrenia, with optimal dose around 4 mg/day balancing efficacy and EPS.

  2. Risperidone for the treatment of irritability in children and adolescents with autistic disorder (RUPP trial) McCracken JT et al. · New England Journal of Medicine, 2002 DOI

    Landmark NIMH-funded RCT establishing risperidone as effective for irritability in autism, with 69% response rate versus 12% on placebo, leading to first FDA approval of an antipsychotic for autism.

  3. Clinical pharmacokinetics of risperidone Mannens G et al. · Clinical Pharmacokinetics, 1994 DOI

    PK study establishing risperidone half-life of 3 hours (extensive CYP2D6 metabolizers) versus 20 hours (poor metabolizers), with active metabolite paliperidone half-life of 21 hours dominating clinical duration.

3 published studies referenced in the app, each with a plain-language summary.